Learning Hub Central

2026 SPS Twin Cities | Hyaluronidase Delivering New Subcutaneous Dosage Forms Throughout Various Therapeutic Areas: A Dive into Clinical, Safety, Practice and Economic Considerations

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | CMS Drug Price Negotiations Through Maximum Fair Price (MFP): Access & Practice Considerations Now & Then

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | Datopotamab Deruxtecan Therapy Considerations in the Management of Unresectable or Metastatic Hormone Receptor-Positive

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | The Evolving Role of Caplacizumab in the Management of Thrombotic Thrombocytopenic Purpura (TTP)

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | Beyond FOLFIRINOX: Updates in the Pancreatic Cancer Space

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | Treosulfan Clinical and Practice Considerations in the Management of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | Gedatolisib in the Management of HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | Emerging 505(b)(2) Therapeutic Optionality: From Opportunity Assessment to Implementation Best Practices

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | Telisotuzumab Clinical Considerations in the Management of Non-Small Cell Lung Cancer (NSCLC)

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | Beyond Steroids: Precision Biologic Approaches to Immune Related Adverse Event Management

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | Formulary Management as a Value Strategy Engine in Both Acute and Ambulatory Settings

0.00 Credits

1 Chapter

Pharmacology

Free

$2026 SPS Twin Cities | Emerging Therapies in Relapsed/Refractory Follicular Lymphoma$

2026 SPS Twin Cities | Emerging Therapies in Relapsed/Refractory Follicular Lymphoma

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Twin Cities | Narsoplimab Clinical & Practice Considerations in Management of Hematopoietic Stem Cell Transplant

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Puerto Rico | Specialty Pharmaceuticals: The Payer Perspective

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Puerto Rico | Building Cell and Gene Therapy Program to Close Equity Gaps

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Puerto Rico | Taletrectinib Pushing Boundaries in ROS1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Puerto Rico | Telisotuzumab in the Management of Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Puerto Rico | GLP-1 Updates with Focus on Medicare Bridge Program Effective July 2026

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Puerto Rico | Caplacizumab in the Immune-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Setting. A Real-World Evidence Review of CAPLA 1000+ and MAYARI Trial

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Puerto Rico | Update on First and Only CAR-T Therapy Program in Puerto Rico

0.00 Credits

1 Chapter

Pharmacology

Free

$2026 SPS Puerto Rico | Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma. A Review of Phase III IRAKLIA Study$

2026 SPS Puerto Rico | Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma. A Review of Phase III IRAKLIA Study

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Denver | Two Paths, One Goal: Harnessing Bispecifics and CAR-Ts Against Hematologic Malignancies

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Denver | Hepatic Artery Infusion (HAI) Chemotherapy

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Denver | Clinical Updates and Real-World Application

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Denver | HELIOS B Clinical Trial: Vutrisiran in the Management of Transthyretin-Mediated Amyloidosis Cardiomyopathy Patients

0.00 Credits

1 Chapter

Pharmacology

Free

Contact Us

Learning Hub Central

Pharmacology

2026 SPS Twin Cities | Hyaluronidase Delivering New Subcutaneous Dosage Forms Throughout Various Therapeutic Areas: A Dive into Clinical, Safety, Practice and Economic Considerations

2026 SPS Twin Cities | CMS Drug Price Negotiations Through Maximum Fair Price (MFP): Access & Practice Considerations Now & Then

2026 SPS Twin Cities | Datopotamab Deruxtecan Therapy Considerations in the Management of Unresectable or Metastatic Hormone Receptor-Positive

2026 SPS Twin Cities | The Evolving Role of Caplacizumab in the Management of Thrombotic Thrombocytopenic Purpura (TTP)

2026 SPS Twin Cities | Beyond FOLFIRINOX: Updates in the Pancreatic Cancer Space

2026 SPS Twin Cities | Treosulfan Clinical and Practice Considerations in the Management of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome

2026 SPS Twin Cities | Gedatolisib in the Management of HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

2026 SPS Twin Cities | Emerging 505(b)(2) Therapeutic Optionality: From Opportunity Assessment to Implementation Best Practices

2026 SPS Twin Cities | Telisotuzumab Clinical Considerations in the Management of Non-Small Cell Lung Cancer (NSCLC)

2026 SPS Twin Cities | Beyond Steroids: Precision Biologic Approaches to Immune Related Adverse Event Management

2026 SPS Twin Cities | Formulary Management as a Value Strategy Engine in Both Acute and Ambulatory Settings

2026 SPS Twin Cities | Emerging Therapies in Relapsed/Refractory Follicular Lymphoma

2026 SPS Twin Cities | Narsoplimab Clinical & Practice Considerations in Management of Hematopoietic Stem Cell Transplant

2026 SPS Puerto Rico | Specialty Pharmaceuticals: The Payer Perspective

2026 SPS Puerto Rico | Building Cell and Gene Therapy Program to Close Equity Gaps

2026 SPS Puerto Rico | Taletrectinib Pushing Boundaries in ROS1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

2026 SPS Puerto Rico | Telisotuzumab in the Management of Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

2026 SPS Puerto Rico | GLP-1 Updates with Focus on Medicare Bridge Program Effective July 2026

2026 SPS Puerto Rico | Caplacizumab in the Immune-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Setting. A Real-World Evidence Review of CAPLA 1000+ and MAYARI Trial

2026 SPS Puerto Rico | Update on First and Only CAR-T Therapy Program in Puerto Rico

2026 SPS Puerto Rico | Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma. A Review of Phase III IRAKLIA Study

2026 SPS Denver | Two Paths, One Goal: Harnessing Bispecifics and CAR-Ts Against Hematologic Malignancies

2026 SPS Denver | Hepatic Artery Infusion (HAI) Chemotherapy

2026 SPS Denver | Clinical Updates and Real-World Application

2026 SPS Denver | HELIOS B Clinical Trial: Vutrisiran in the Management of Transthyretin-Mediated Amyloidosis Cardiomyopathy Patients

Contact Us